文献速递胃肠外科围术期管理与 ERAS

276例原发性小胃胃肠间质瘤的临床病理特征与预后:多中心数据回顾

Clinicopathological features and prognosis of 276 cases of primary small (≤ 2 cm) gastric gastrointestinal stromal tumors: a multicenter data review.
PubMed 文献 · Surg Endosc · 2018-11-27

该多中心回顾性研究纳入1998年至2015年间4个中心收治的276例原发性小胃胃肠间质瘤(≤2 cm)患者,分析其临床病理特征、治疗方式及预后。结果显示腹腔镜、开腹及内镜切除分别占49.6%、27.2%和23.2%,5年总生存率达99.1%,但中高危病例的识别仍是未来重点。

要点

  • 小胃GIST总体预后良好,5年总生存率99.1%。
  • 手术或内镜切除是主要治疗方式,腹腔镜切除占49.6%。
  • 需重视中高危病例的识别以及时干预。

核心结论

  • 原发性小胃GIST发病率逐年增加,但总体生存预后良好。
  • 手术或内镜切除是主要治疗方式。
  • 小胃GIST病理特征与大GIST相似,中高危病例识别是未来研究重点。

研究设计与样本

  • 多中心回顾性数据 review,纳入1998年1月至2015年1月中国南方4个中心收治的276例原发性小胃GIST(≤2 cm)患者。
  • 中位年龄60岁(范围27-91岁)。

主要发现

  • 肿瘤部位:贲门24例(8.7%),胃底107例(38.8%),胃体117例(42.4%),胃窦28例(10.1%)。
  • 术前活检11例(4.0%)。
  • 手术方式:腹腔镜137例(49.6%),开腹75例(27.2%),内镜切除64例(23.2%)。
  • 核分裂计数≤5/50 HPF 259例(93.8%),(5-10)/50 HPF 7例(2.5%),>10/50 HPF 10例(3.6%)。
  • 免疫组化:CD34+ 74.6%(206/276),CD117+ 98.2%(271/276),DOG-1+ 97.4%(269/276)。

关键数值与推荐

  • 小胃GIST定义为肿瘤直径≤2 cm。
  • 核分裂计数分类:≤5/50 HPF、5-10/50 HPF、>10/50 HPF。
  • 高危患者可考虑伊马替尼辅助治疗(原文中5例高危患者接受伊马替尼)。

临床怎么用

  • 对于≤2 cm的胃GIST,手术或内镜切除是主要治疗方式,可根据肿瘤部位和特征选择腹腔镜、开腹或内镜切除。
  • 术后需根据核分裂计数等病理特征评估风险,中高危患者应加强随访,必要时给予伊马替尼辅助治疗。

局限性

  • 回顾性多中心数据,可能存在选择偏倚和信息偏倚。
  • 样本量有限,尤其基因检测仅39例(14.1%),中高危病例较少。
  • 随访时间中位38个月,部分患者随访时间较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Till present, there are still controversies over the epidemiology, pathological features, types of surgical treatment, and prognoses of primary small gastric GISTs (gGISTs). METHODS: From January 1998 to January 2015, patients with primary small gGIST admitted from four high-volume medical centers of the Southern China were enrolled and their data were analyzed to evaluate their clinicopathological features, treatment and prognostic factors to provide evidence-based medical experience for clinical practice. RESULTS: A total of 276 primary small gGIST cases over a period of 18 years were investigated and had a median age of 60 years (range 27-91 years old). Regarding the tumor sites, 24 (8.7%) cases were in the cardia of the stomach, 107 (38.8%) in the fundus, 117 (42.4%) in the gastric body, and 28 (10.1%) in the gastric antrum. Eleven patients (4.0%) underwent a preoperative biopsy. A total of 137 (49.6%), 75 (27.2%), and 64 (23.2%) patients underwent laparoscopic, open resection, and endoscopic resection, respectively. Sixty-four patients (23.2%) had local endoscopic resection, 172 (62.3%) had wedge resection, 7 (2.5%) had proximal gastrectomy, 19 (6.9%) had distal gastrectomy, and 14 (5.1%) had total gastrectomy. Mitotic counts were ≤ 5/50, (5-10)/50, and > 10/50 per HPF in 259 (93.8%), 7 (2.5%), and 10 (3.6%) cases, respectively. There were 259 cases (97.1%) of spindle cell type, 7 (2.5%) epithelial cell types and one case (0.4%) of mixed type. Immunohistochemistry showed 74.6% (206/276), 98.2% (271/276), and 97.4% (269/276) of the patients had co-expression of CD34+, CD117+, and DOG-1+, respectively. Thirty-nine patients underwent genetic testing (39/276, 14.1%). Three patients (1.1%) had positive resection margin. Five high-risk patients received follow-up treatment with imatinib with a median follow-up time of 38 months (range 3-156 months). The overall 1-, 3-, and 5-year overall survival rates were 100%, 99.6%, and 99.1%, respectively. CONCLUSION: Though the incidence of primary small gGISTs increased per annum, the overall survival prognoses were high. Surgery or endoscopic resection was the primary mode of treatment. Pathological features of primary small gGISTs were similar to large gGISTs, and to achieve a timely surgical intervention, the identification of intermediate- and high-risk cases should be a future focus of study.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Yang Z, Feng X, Zhang P, et al. Clinicopathological features and prognosis of 276 cases of primary small (≤ 2 cm) gastric gastrointestinal stromal tumors: a multicenter data review. Surg Endosc. 2018. PMID: 30483969. doi:10.1007/s00464-018-6564-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。